David Michel, MD
Orthopaedic Surgery · Austin, TXNPI 1457779928
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. Stryker accounts for 91.4% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $4,816, 3.3 times the $1,461 reported in 2020.
Across 62 payments — averaging $127.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$7K
- Davol Inc.$203
- Welch Allyn$186
- SPR Therapeutics, Inc$120
- Solventum Corporation$100
- Smith+Nephew$70
What the payments were for
- Travel & lodging$3,20640%
- Food & beverage$3,54045%
- Education$1,00013%
- Other$1862%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 55 | $7,253 |
| Davol Inc. | 2 | $203 |
| Welch Allyn | 1 | $186 |
| SPR Therapeutics, Inc | 1 | $120 |
| Solventum Corporation | 1 | $100 |
| Smith+Nephew | 2 | $70 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$5,839
- SPOT Vision Screener$186
- NONE$133
- ARISTA$130
- SPRINT PNS System$120
- PREVENA$100
- PREVENA RESTOR ARTHROFORM$100
How this compares
$7,931 in reported general payments places this provider in the 60th percentile of 1,337 orthopaedic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 24 | $8,072 |
| Celecoxib | 167 | $2,243 |
| Oxycodone Hcl | 282 | $1,969 |
| Ondansetron OdtOndansetron | 166 | $1,629 |
| Cefadroxil | 102 | $844 |
| Methylprednisolone | 114 | $677 |
| Clindamycin Hcl | 27 | $237 |
| Tramadol Hcl | 56 | $139 |
| Gabapentin | 19 | $97 |
| Amoxicillin | 72 | $58 |
| Meloxicam | 32 | $53 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Austin
- Robert GrahamAustin$6.3M
- Eric HeinrichAustin$907K
- David DodginAustin$704K
- Stephen BurkhartSan Antonio$185.3M
- Kirby HittTemple$9.1M
- Richard JonesDallas$6.3M
- Stefan KreuzerHouston$6.2M
- Michael WirthSan Antonio$4.5M
- Stephen IncavoHouston$4.3M
- Thomas EdwardsHouston$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.